Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors.

导出原文传递

翻译打印收藏纠错

第一作者： Bonnie S,Glisson

第一单位： The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. bglisson@mdanderson.org.

作者： Bonnie S,Glisson ^[1] ; Rom S,Leidner ^[2] ; Robert L,Ferris ^[3] ; John,Powderly ^[4] ; Naiyer A,Rizvi ^[5] ; Bhumsuk,Keam ^[6] ; Reva,Schneider ^[7] ; Sanjay,Goel ^[8] ; James P,Ohr ^[3] ; Jennifer,Burton ^[9] ; Yanan,Zheng ^[10] ; Steven,Eck ^[10] ; Matthew,Gribbin ^[10] ; Katie,Streicher ^[10] ; Danielle M,Townsley ^[10] ; Sandip Pravin,Patel ^[11]

作者单位： The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. bglisson@mdanderson.org. ^[1] EACRI - Providence Cancer Center, Portland, Oregon, USA. ^[2] UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. ^[3] Carolina BioOncology Institute, Huntersville, North Carolina, USA. ^[4] Columbia University Medical Center, New York, New York, USA. ^[5] Seoul National University Hospital, Seoul, South Korea. ^[6] Mary Crowley Cancer Research - Medical City Dallas, Dallas, Texas, USA. ^[7] Montefiore Einstein Cancer Center, Bronx, New York, USA. ^[8] AstraZeneca, Cambridge, United Kingdom. ^[9] AstraZeneca, Gaithersburg, Maryland, USA. ^[10] UC San Diego Moores Cancer Center, La Jolla, California, USA. ^[11]